OTCMKTS:CRLBF - Cresco Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.53
  • Forecasted Upside: 9.90 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$13.22
▲ +0.1265 (0.97%)
1 month | 3 months | 12 months
Get New Cresco Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRLBF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRLBF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.53
▲ +9.90% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cresco Labs in the last 3 months. The average price target is $14.53, with a high forecast of $24.00 and a low forecast of $4.20. The average price target represents a 9.90% upside from the last price of $13.22.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Cresco Labs.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/18/2021Haywood SecuritiesBoost Price TargetNA$24.00
i
1/13/2021Canaccord GenuityBoost Price TargetBuy$16.00 ➝ $20.50
i
11/19/2020Piper SandlerBoost Price TargetOverweight$12.00 ➝ $14.00
i
11/19/2020Cantor FitzgeraldBoost Price TargetOverweight$16.00 ➝ $18.00
i
10/30/2020Cantor FitzgeraldBoost Price TargetOverweight$15.00 ➝ $16.00
i
8/21/2020Roth CapitalBoost Price TargetBuy$8.00 ➝ $11.00
i
8/21/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $15.00
i
8/21/2020Piper SandlerBoost Price TargetOverweight$8.00 ➝ $12.00
i
7/22/2020Stifel NicolausInitiated CoverageBuy$10.00
i
6/12/2020Needham & Company LLCInitiated CoverageHold$4.20
i
5/29/2020Canaccord GenuityReiterated RatingBuy$11.50
i
5/27/2020Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $9.50
i
4/28/2020Canaccord GenuityLower Price TargetBuy$12.50 ➝ $11.50
i
4/28/2020Cantor FitzgeraldLower Price TargetOverweight$10.00 ➝ $8.00
i
3/30/2020Cantor FitzgeraldLower Price TargetOverweight$12.00 ➝ $10.00
i
2/21/2020LADENBURG THALM/SH SHInitiated CoverageBuy
i
2/13/2020Cantor FitzgeraldInitiated CoverageOverweight$12.00
i
12/20/2019Roth CapitalInitiated CoverageBuy$12.00
i
Rating by Scott Fortune at Roth Capital
9/13/2019CowenInitiated CoverageOutperform$14.00
i
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$11.00
i
6/10/2019Compass PointInitiated CoverageBuy
i
(Data available from 1/18/2016 forward)
Cresco Labs logo
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flowers, live concentrates, and liquid live resins under the Cresco and Reserve brands; soft gels, tinctures, and lotions under the Remedi brand; gummies, fruit chews, hard sweets, and chocolates under the Mindy's brand; and vape pens, popcorn, shake, pre-rolls, and shorties under High supply brand. It operates 22 dispensaries in Illinois, Pennsylvania, Ohio, California, Nevada, Arizona, Massachusetts, and New York. The company is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $13.22
$12.75
$13.85

50 Day Range

MA: $10.47
$9.87
$13.09

52 Week Range

Now: $13.22
$1.94
$14.24

Volume

2,196,400 shs

Average Volume

1,725,900 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cresco Labs?

The following sell-side analysts have issued stock ratings on Cresco Labs in the last year: Canaccord Genuity, Cantor Fitzgerald, Haywood Securities, LADENBURG THALM/SH SH, Needham & Company LLC, Piper Sandler, Roth Capital, and Stifel Nicolaus.

What is the current price target for Cresco Labs?

7 Wall Street analysts have set twelve-month price targets for Cresco Labs in the last year. Their average twelve-month price target is $14.53, suggesting a possible upside of 9.9%. Haywood Securities has the highest price target set, predicting CRLBF will reach $24.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $4.20 for Cresco Labs in the next year.

What is the current consensus analyst rating for Cresco Labs?

Cresco Labs currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRLBF will outperform the market and that investors should add to their positions of Cresco Labs.

What other companies compete with Cresco Labs?

How do I contact Cresco Labs' investor relations team?

The company's listed phone number is 312-929-0993. The official website for Cresco Labs is www.crescolabs.com.